|
시장보고서
상품코드
1764891
북미의 녹내장 치료제 시장 : 예측 - 지역별 분석(약제 클래스별, 적응증별, 유통 채널별)(-2031년)North America Glaucoma Therapeutics Market Forecast to 2031 - Regional Analysis - by Drug Class, Indication, and Distribution Channel |
||||||
북미의 녹내장 치료제 시장은 2023년에 26억 3,452만 달러로 평가되었고, 2031년에는 34억 2,164만 달러에 이를 것으로 예측되며, 2023년부터 2031년까지의 CAGR은 3.3%를 나타낼 전망입니다.
녹내장 질환 증가로 북미 녹내장 치료제 시장 활성화
녹내장은 시신경 손상으로 인한 눈 질환으로 궁극적으로 실명에 이르게 될 수 있습니다. 녹내장 연구 재단에 따르면, 2040년까지 전 세계적으로 약 2,200만명이 녹내장에 의해 실명할 것이라고 예상됩니다. 또한, 세계보건기구(WHO)에 의하면, 녹내장은 세계에서의 실명의 주요 원인이며, 6,000만명 이상이 이환되어, 약 450만명이 실명하고 있습니다. Association for Research in Vision and Ophthalmology(ARVO) Journal에 게재된 논문에 따르면, 멕시코의 녹내장 환자 수는 2030년 말에는 250만명, 2040년 말에는 300만명, 2050년 말에는 340만명에 이를 것으로 추정되고 있습니다. 질병을 관리하기 위한 내과적 및 외과적 치료는 안압(IOP)을 낮추는데 중점을 두고 있습니다.
북미의 녹내장 치료제 시장 개요
인구문제연구소 2019에 따르면 미국의 65세 이상의 고령자 수는 2018년 5,200만명(총 인구의 16%)에서 배가 늘었고, 2060년에는 9,500만명 가까이(총인구의 23%)가 될 것으로 추정되고 있습니다. 70-75세의 732만명 가까이가 원전 개방 구석 각 녹내장(POAG)에 걸린 것으로 추정되고 있습니다. 그러므로, 미국에 있어서의 녹내장 치료제 시장의 성장은 특히 노인 인구에 있어서의 안질환의 유병률 증가가 주된 요인이 되고 있습니다. 미국은 북미의 녹내장 치료제 시장에서 가장 큰 비중을 차지하고 있습니다.
각 기업이 채택한 다양한 유기적 및 무기적 성장 전략은 미국의 녹내장 치료제 시장의 발전에 크게 기여하고 있습니다.
2023년 10월, Stuart Therapeutics와 Glaukos는 녹내장의 신경 보호를 위해 설계된 Stuart Therapeutics의 ST-113 약물 후보에 대한 라이선스 계약을 체결했습니다. 2022년 8월, Alcon은 Aerie Pharmaceuticals를 인수했습니다. 이 인수는 Alcon의 안과용 의약품 분야에 대한 헌신을 확인하는 것으로, 보다 광범위한 의약품의 연구개발 능력을 추가함으로써 기존의 상업적 전문성을 강화하고 다양한 포트폴리오의 가치를 극대화할 것으로 기대됩니다.
북미의 녹내장 치료제 : 시장 구분
북미의 녹내장 치료제 시장은 약물 클래스별, 적응증별, 유통채널별, 국가별로 분류됩니다.
약물 등급별로 북미의 녹내장 치료제 시장은 베타 차단제, 알파 아드레날린 작용제, 프로스타글란딘 유사체, 탄산 탈수 효소 억제제, 병용 약물 등으로 구분됩니다.
적응증의 관점에서 북미 녹내장 치료제 시장은 개방 각도 녹내장, 폐쇄각 녹내장 등으로 분류됩니다.
유통 채널별로 북미의 녹내장 치료제 시장은 병원 약국, 소매 약국, 온라인 약국으로 분류됩니다.
국가별로는 북미의 녹내장 치료제 시장은 미국, 캐나다, 멕시코로 구분됩니다.
Alcon AG, AbbVie Inc, Bausch &Lomb Inc, Fera Pharmaceuticals, LLC, Viatris Inc, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals Industries Ltd, Thea Pharma Inc, Santen Pharmaceutical Co., Ltd.등 입니다.
목차
제1장 서론
제2장 주요 요약
- 주요 인사이트
- 시장의 매력
제3장 분석 방법
- 2차 조사
- 1차 조사
- 가설의 책정
- 거시경제 요인분석
- 기초 수치의 개발
- 데이터의 삼각측량
- 국가 수준 데이터
제4장 북미의 녹내장 치료제 시장의 정세
- 개관
- PEST 분석
제5장 북미의 녹내장 치료제 시장 : 주요 시장 역학
- 녹내장 치료제 시장 : 주요 시장 역학
- 시장 성장 촉진요인
- 녹내장 이환율 증가
- 제품 출시, 제휴, 인수 증가
- 시장 성장 억제요인
- 복약 컴플라이언스 문제
- 시장 기회
- 웨어러블 기술 개발
- 향후의 동향
- 새로운 약물전달법의 개발
- 성장 촉진요인과 억제요인의 영향
제6장 녹내장 치료제 시장 : 북미 시장의 분석
- 녹내장 치료제 시장의 수익(2021-2031년)
- 녹내장 치료제 시장 예측·분석
제7장 북미의 녹내장 치료제 시장 분석 : 약제 클래스별
- β차단제
- α아드레날린 작용제
- 프로스타글란딘 유사체
- 탄산탈수효소 억제제
- 병용약
- 기타
제8장 북미의 녹내장 치료제 시장 분석 : 적응증별
- 개방각 녹내장
- 폐쇄각 녹내장
- 기타
제9장 북미의 녹내장 치료제 시장 분석 : 유통 채널별
- 병원 약국
- 소매 약국
- 온라인 약국
제10장 북미의 녹내장 치료제 시장 분석 : 국가별
- 북미
- 미국
- 캐나다
- 멕시코
제11장 녹내장 치료제 시장 : 업계 정세
- 녹내장 치료제 시장의 성장 전략
- 유기적 성장 전략
- 무기적 성장 전략
제12장 기업 프로파일
- Alcon AG
- AbbVie Inc
- Bausch & Lomb Inc
- Fera Pharmaceuticals, LLC
- Viatris Inc
- Novartis AG
- Sun Pharmaceutical Industries Ltd
- Teva Pharmaceutical Industries Ltd
- Thea Pharma Inc
- Santen Pharmaceutical Co., Ltd.
제13장 부록
SHW 25.07.14The North America glaucoma therapeutics market was valued at US$ 2,634.52 million in 2023 and is expected to reach US$ 3,421.64 million by 2031; it is estimated to register a CAGR of 3.3% from 2023 to 2031.
Mounting Incidence of Glaucoma Disease Fuels North America Glaucoma Therapeutics Market
Glaucoma is an eye disorder caused due to the damaged optic nerve, which can eventually lead to total blindness. Glaucoma patients may experience a gradual loss of nerve tissue, resulting in vision impairment or blindness if left untreated. Glaucoma cases are increasing significantly across the world. As per the Glaucoma Research Foundation, an estimated 22 million people worldwide would attain blindness due to glaucoma by 2040. Further, Glaucoma is a leading cause of blindness worldwide, affecting over 60 million people and leading to approximately 4.5 million cases of blindness, according to the World Health Organization. According to estimates provided in an article published in the Association for Research in Vision and Ophthalmology (ARVO) Journal in January 2021, the number of people suffering from glaucoma in Mexico would reach 2.5 million, 3 million, and 3.4 million by the end of 2030, 2040, and 2050, respectively. The demand for glaucoma treatments is increasing with the rising number of glaucoma cases in the global population. Medical and surgical procedures meant to manage this disease focus on lowering intraocular pressure (IOP). Prostaglandin analogs are among the drugs widely recommended for effectively reducing IOP by promoting better drainage from the eye. These products have been mainstream glaucoma treatment due to their efficacy and limited adverse effects.
North America Glaucoma Therapeutics Market Overview
As per the Population Reference Bureau 2019, the number of individuals aged 65 and above in the US is estimated to double from 52 million (16% of the total population) in 2018 to nearly 95 million (23% of the total population) by 2060. A study conducted by the American Academy of Ophthalmology in 2019 states that nearly 7.32 million people aged 70-75 is estimated to be affected by primary open-angle glaucoma (POAG) in the US by 2050. Thus, the glaucoma therapeutics market growth in the US is primarily driven by the increasing prevalence of eye diseases, especially in the geriatric population. The US accounts for the largest share of the glaucoma therapeutics market in North America.
Various organic and inorganic growth strategies adopted by market players also contribute notably to the glaucoma therapeutics market progress in the US. A few of such growth strategies are mentioned below.
In October 2023, Stuart Therapeutics and Glaukos signed a license agreement for Stuart Therapeutics' ST-113 drug candidate designed for neuroprotection in glaucoma. In August 2022, Alcon acquired Aerie Pharmaceuticals, Inc. This transaction confirms Alcon's commitment to the ophthalmic pharmaceutical space, and it is expected to enhance its existing commercial expertise by adding broader pharmaceutical R&D capabilities, thereby maximizing the value of its diversified portfolio. North America Glaucoma Therapeutics Market Revenue and Forecast to 2031 (US$ Million)
North America Glaucoma Therapeutics Market Segmentation
The North America glaucoma therapeutics market is categorized into drug class, indication, distribution channel, and country.
Based on drug class, the North America glaucoma therapeutics market is segmented into beta blockers, alpha adrenergic agonists, prostaglandins analogues, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandins analogues segment held the largest market share in 2023.
In terms of indication, the North America glaucoma therapeutics market is categorized into open angle glaucoma, angle closure glaucoma, and others. The open angle glaucoma segment held the largest market share in 2023.
By distribution channel, the North America glaucoma therapeutics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment held the largest market share in 2023.
By country, the North America glaucoma therapeutics market is segmented into the US, Canada, and Mexico. The US dominated the North America glaucoma therapeutics market share in 2023.
Alcon AG, AbbVie Inc, Bausch & Lomb Inc, Fera Pharmaceuticals, LLC, Viatris Inc, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals Industries Ltd, Thea Pharma Inc, and Santen Pharmaceutical Co., Ltd. are among the leading companies operating in the North America glaucoma therapeutics market.
Table Of Contents
1. Introduction
- 1.1 The Insight Partners Research Report Guidance
- 1.2 Market Segmentation
2. Executive Summary
- 2.1 Key Insights
- 2.2 Market Attractiveness
3. Research Methodology
- 3.1 Secondary Research
- 3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
4. North America Glaucoma Therapeutics Market Landscape
- 4.1 Overview
- 4.2 PEST Analysis
5. North America Glaucoma Therapeutics Market - Key Market Dynamics
- 5.1 Market Drivers
- 5.1.1 Mounting Incidence of Glaucoma Disease
- 5.1.2 Increasing Number of Product Launches, Collaborations, and Acquisitions
- 5.2 Market Restraints
- 5.2.1 Medication Regimen Compliance Issues
- 5.3 Market Opportunities
- 5.3.1 Development of Wearable Technologies
- 5.4 Future Trends
- 5.4.1 Development of Novel Drug Delivery Methods
- 5.5 Impact of Drivers and Restraints:
6. Glaucoma Therapeutics Market - North America Analysis
- 6.1 Glaucoma Therapeutics Market Revenue (US$ Million), 2021-2031
- 6.2 Glaucoma Therapeutics Market Forecast Analysis
7. North America Glaucoma Therapeutics Market Analysis - by Drug Class
- 7.1 Beta Blockers
- 7.1.1 Overview
- 7.1.2 Beta Blockers: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 7.2 Alpha Adrenergic Agonists
- 7.2.1 Overview
- 7.2.2 Alpha Adrenergic Agonists: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 7.3 Prostaglandins Analogues
- 7.3.1 Overview
- 7.3.2 Prostaglandins Analogues: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 7.4 Carbonic Anhydrase Inhibitors
- 7.4.1 Overview
- 7.4.2 Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 7.5 Combination Drugs
- 7.5.1 Overview
- 7.5.2 Combination Drugs: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
8. North America Glaucoma Therapeutics Market Analysis - by Indication
- 8.1 Open Angle Glaucoma
- 8.1.1 Overview
- 8.1.2 Open Angle Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 8.2 Angle Closure Glaucoma
- 8.2.1 Overview
- 8.2.2 Angle Closure Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 8.3 Others
- 8.3.1 Overview
- 8.3.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
9. North America Glaucoma Therapeutics Market Analysis - by Distribution Channel
- 9.1 Hospital Pharmacy
- 9.1.1 Overview
- 9.1.2 Hospital Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 9.2 Retail Pharmacy
- 9.2.1 Overview
- 9.2.2 Retail Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 9.3 Online Pharmacy
- 9.3.1 Overview
- 9.3.2 Online Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
10. North America Glaucoma Therapeutics Market - Country Analysis
- 10.1 North America
- 10.1.1 North America: Glaucoma Therapeutics Market Breakdown, by Key Country, 2023 and 2031 (%)
- 10.1.1.1 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
- 10.1.1.2 United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 10.1.1.2.1 United States: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 10.1.1.2.2 United States: Glaucoma Therapeutics Market Breakdown, by Indication
- 10.1.1.2.3 United States: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 10.1.1.3 Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 10.1.1.3.1 Canada: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 10.1.1.3.2 Canada: Glaucoma Therapeutics Market Breakdown, by Indication
- 10.1.1.3.3 Canada: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 10.1.1.4 Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 10.1.1.4.1 Mexico: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 10.1.1.4.2 Mexico: Glaucoma Therapeutics Market Breakdown, by Indication
- 10.1.1.4.3 Mexico: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 10.1.1 North America: Glaucoma Therapeutics Market Breakdown, by Key Country, 2023 and 2031 (%)
11. Glaucoma Therapeutics Market - Industry Landscape
- 11.1 Growth Strategies in Glaucoma Therapeutics Market
- 11.2 Organic Growth Strategies
- 11.2.1 Overview
- 11.3 Inorganic Growth Strategies
- 11.3.1 Overview
12. Company Profiles
- 12.1 Alcon AG
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
- 12.2 AbbVie Inc
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
- 12.3 Bausch & Lomb Inc
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
- 12.4 Fera Pharmaceuticals, LLC
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
- 12.5 Viatris Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
- 12.6 Novartis AG
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
- 12.7 Sun Pharmaceutical Industries Ltd
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
- 12.8 Teva Pharmaceutical Industries Ltd
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
- 12.9 Thea Pharma Inc
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
- 12.10 Santen Pharmaceutical Co., Ltd.
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments
13. Appendix
- 13.1 About The Insight Partners
- 13.2 Glossary of Terms
